Veradigm Inc.: Business Overview, Financials & Competitive Analysis
Veradigm Inc. is a healthcare technology company that provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company has a proven...
Cyborg Score thesis
Veradigm operates a sticky healthcare IT platform with strategic data assets, but faces near-term execution risks tied to...
Read the full analyst-debate transcript →Get the Latest Veradigm Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeVeradigm Inc. Overview
Pro stress-test →Veradigm Inc. is a healthcare technology company that provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company has a proven history of delivering clinical and revenue cycle solutions that help over 20,000 independent provider practices improve outcomes and financial performance through AI-forward data and technology.
Strategic Profile
Pro stress-test →Veradigm offers comprehensive solutions including risk adjustment analytics, quality management, data exchange and coding, clinical data registries, real-world data analytics, and digital health media solutions. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023.
Competitive Landscape
Pro stress-test →Veradigm competes in the healthcare IT and analytics space against established players in EHR, practice management, and revenue cycle solutions. The company's competitive position relies on its large provider network, integrated platform capabilities, and real-world data assets. Key competitive challenges include regulatory compliance requirements and the need to drive growth while managing profitability.
Industry Context
Veradigm Inc. operates in Healthcare IT / Health Information Technology.
Key facts
Founded: 1986 · Headquarters: Chicago, Illinois · Revenue: $583-588M (2025 guidance)